SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
BioMed News Bytes: Arena (NASDAQ: ARNA), ImmunoCellular (OTC: IMUC.OB), YM Bio (AMEX: YMI)
ARNA
|
|
|
+0.00%
in
15 hours
(closed on 09/18/09)
Shares of Arena Pharma (NASDAQ: ARNA) (AH $6.58, +34% at 5:10pm ET on heavy, above-average volume for the day) are surging on news that the Company will <font> conduct a conference call Friday 18-September at 8am ET </font> to discuss the BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 study (its second pivotal Phase 3 study for this compound) results for its experimental weight loss drug lorcaserin and expects to submit a NDA for FDA approval by year-end based on guidance provided in late March, which is outlined below. <> ...
|
FDA Calendar: Five Weight Loss Trades
ARNA
|
|
|
+14.72%
in
58 days
(closed on 09/17/09)
<> Below are five small/micro-cap companies from the <font> BioMedReports.com FDA Calendar </font> with late-stage drugs or medical devices in development for prescription weight loss. Nearly two-thirds or 65% of U.S. population is classified as obese or overweight with a three-fold increase in adolescent obesity rates over the past three decades. Obesity is the second leading cause of preventable deaths behind smoking and weight loss is proven to decrease mortality while also improving blood sugar control in diabetics. Over one-third (35%) of people in the U.S. have a lifetime of devel...
|
Extreme FDA Calendar Trades: 18 Stocks Under $5
ARNA
|
|
|
+11.75%
in
18 days
(closed on 07/21/09)
<> Below are extreme trades among companies with stock prices under $5 from the <font> BioMedReports.com FDA Calendar </font> , which includes 232 entries as of 7/3/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissio...
|
Arena Pharmaceuticals Inc
ARNA
|
|
|
-27.20%
in
154 days
Last trade signal was SELL
at 2009-May-13
Price: $2.72
<table width="600"> <tbody> <tr> <td> <table> <tbody> <tr> <td> </td> <td> for ARNA </td> <td> </td> </tr> <...
|
FDA Calendar Updates: MITI, KERX, GSK, DYAX, ARNA, PGNX
ARNA
|
|
|
-1.82%
in
25 days
(closed on 07/03/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of about 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-s...
|
From the Blogosphere
Zacks Analyst Blog Highlights: Clorox Company, Arena Pharmaceuticals, Vivus Inc., Orexigen Therapeutics and Amylin Pharmaceuticals – Press Releases
|
|
|
For Immediate Release Chicago, IL – November 3, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Clorox Company (CLX), Arena Pharmaceuticals (ARNA), Vivus Inc. (VVUS), Orexigen Therapeutics (OREX) and Amylin Pharmaceuticals (AMLN). Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513 <><>Here are highlights from Monday’s An<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>< />< />< />< /><><><><>< /><><>< /><>< /><>< />< />...
|
Amylin Strikes First on Obesity – Analyst Blog
|
|
|
Almost all of the news in the obesity race has been made recently by three small biotech companies -- Arena Pharmaceuticals (ARNA), Vivus Inc. (VVUS) and Orexigen Therapeutics (OREX), but yesterday it was mid-cap Amylin Pharmaceuticals (AMLN) that signed the first partnership in what was originally perceived to be a three-horse race.
Amylin and Takeda Pharmaceutical Company Limited entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pramlintide/metreleptin and davalintide, two phase II compounds for the treatment of obesi...
|
BioMed News Bytes: Arena, ImmunoCellular, YM Bio
Shares of Arena Pharma (ARNA) (AH $6.58, +34% at 5:10pm ET on heavy, above-average volume for the day) are surging on news that the Company will <font>conduct a conference call Friday 18-September at 8am ET</font> to discuss the BLOSSOM (Behavioral modification and Lorcaserin Second Study for Obesity Management) Phase 3 study (its second pivotal Phase 3 study for this compound) results for its experimental weight loss drug lorcaserin and expects to submit a NDA for FDA approval by year-end based on guidance provided in late March, which is outlined below. <><>On 3/30/09, ARNA announced top-lin...
|
Arena's Edge in the Obesity Drug Race
As the U.S. obesity epidemic grows ever bigger–pardon the pun–with aging Baby Boomer and Generation X waistlines expanding and record numbers of obese Gen. Y children burgeoning into adulthood, three companies are vying to become first to market with potential blockbuster-status weight loss drugs. Arena Pharmaceuticals (ARNA), Orexigen Therapeutics (OREX) and Vivus Inc. (VVUS) are in play with weight loss drugs in late stage clinical trials, but all face hurdles in their quest for regulatory approval and it remains unclear whether a “blockbuster” victor may emerge. <><> While we believe...
|
A Biotech Triple Play: Dendreon, BioCryst and Arena
|
<>There's only one thing better than catching a big stock market winner like Dendreon (DNDN), and that's letting your profits ride on two or three winners in a row. Even though not one of the seven Wall Street analysts following Dendreon had a buy on the stock before the recent announcement that the final Phase III trial of the company's Provenge prostate cancer drug was a clear success, we had it listed as a Top Buy for many months and subscribers rode it from under $5 to over $20. I've recently asked them to sell some Dendreon and buy a position in BioCryst (BCRX) before a pending announc...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on ARNA |
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Arena Pharmaceuticals Inc
- Answers.com
